These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24204859)

  • 21. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
    Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
    World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distribution of IL28B rs12979860 and rs8099917 Genotypes in Patients with Chronic Hepatitis C Virus Infection in Tianjin, China.
    Qiao K; Trieu C; Huo Z; Du Y; Hou W
    Clin Lab; 2018 Apr; 64(4):543-550. PubMed ID: 29739095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
    Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection.
    Thong VD; Wasitthankasem R; Tangkijvanich P; Vongpunsawad S; Poovorawan Y
    PLoS One; 2015; 10(5):e0125400. PubMed ID: 25938236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.
    Ridruejo E; Solano A; Marciano S; Galdame O; Adrover R; Cocozzella D; Delettieres D; Martínez A; Gadano A; Mandó OG; Silva MO
    Ann Hepatol; 2011; 10(4):452-7. PubMed ID: 21911885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent.
    Ranjan P; Fletcher GJ; Radhakrishnan M; Sivakumar J; Premkumar PS; Goel A; Zachariah UG; Abraham P
    Indian J Med Microbiol; 2016; 34(3):335-41. PubMed ID: 27514956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.
    Heo NY; Lim YS; Lee W; Oh M; An J; Lee D; Shim JH; Kim KM; Lee HC; Lee YS; Suh DJ
    Clin Mol Hepatol; 2014 Jun; 20(2):177-84. PubMed ID: 25032184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
    Lindh M; Lagging M; Arnholm B; Eilard A; Nilsson S; Norkrans G; Söderholm J; Wahlberg T; Wejstål R; Westin J; Hellstrand K
    J Viral Hepat; 2011 Jul; 18(7):e325-31. PubMed ID: 21692944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
    Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
    New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.
    Riva E; Scagnolari C; Monteleone K; Selvaggi C; Picardi A; Mazzarelli C; Pizzigallo E; Vincenzi B; Carducci A; Antonaci S; Giannelli G; Antonelli G
    J Viral Hepat; 2012 Sep; 19(9):650-3. PubMed ID: 22863269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.
    Kawaoka T; Hayes CN; Ohishi W; Ochi H; Maekawa T; Abe H; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Kubo M; Tsunoda T; Nakamura Y; Kumada H; Chayama K
    J Hepatol; 2011 Mar; 54(3):408-14. PubMed ID: 21112660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
    Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K
    Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients.
    Firdaus R; Biswas A; Saha K; Mukherjee A; Chaudhuri S; Chandra A; Konar A; Sadhukhan PC
    PLoS One; 2014; 9(6):e99126. PubMed ID: 24914551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Occult hepatitis C virus infection in hemophilia patients and its correlation with interferon lambda 3 and 4 polymorphisms.
    Nafari AH; Ayadi A; Noormohamadi Z; Sakhaee F; Vaziri F; Siadat SD; Fateh A
    Infect Genet Evol; 2020 Apr; 79():104144. PubMed ID: 31838260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evaluation of interferon lambda 4 rs368234815 as a predictor factor in treated patients with chronic hepatitis C genotype 1a infection.
    Jalilian S; Latifi SM; Makvandi M; Teimoori A; Azaran A; Parsanahad M; Kayedani G
    Indian J Med Microbiol; 2017; 35(2):262-268. PubMed ID: 28681817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection.
    Fischer J; Böhm S; Scholz M; Müller T; Witt H; George J; Sarrazin C; Susser S; Schott E; Suppiah V; Booth DR; Stewart GJ; van Bömmel F; Brodzinski A; Fülöp B; Migaud P; Berg T
    Hepatology; 2012 Jun; 55(6):1700-10. PubMed ID: 22234924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort.
    Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Vincze A; Szereday L; Kisfali P; Melegh B
    BMC Res Notes; 2014 Jan; 7():12. PubMed ID: 24398031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.
    Kobayashi M; Suzuki F; Akuta N; Sezaki H; Suzuki Y; Hosaka T; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Miyakawa Y; Kumada H
    J Gastroenterol; 2012 May; 47(5):596-605. PubMed ID: 22438096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.
    Fateh A; Aghasadeghi MR; Keyvani H; Mollaie HR; Yari S; Hadizade Tasbiti AR; Ghazanfari M; Monavari SH
    Asian Pac J Cancer Prev; 2015; 16(5):1873-80. PubMed ID: 25773839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.